Pancreatic Adenocarcinoma
Pancreatic adenocarcinoma—often called pancreatic ductal adenocarcinoma (PDAC)—is the most common type of pancreatic cancer. It arises from the cells lining the pancreatic ducts and is known for its aggressive behavior and often delayed diagnosis. Tumors in the head of the pancreas frequently cause painless jaundice, while those in the body or tail tend to produce more vague symptoms such as abdominal or back pain, weight loss, and new diabetes. Imaging—particularly CT, MRI with MR cholangiopancreatography (MRCP), and endoscopic ultrasound—is central to diagnosis and staging, and treatment is highly individualized.
What is it?
The pancreas is an organ in the upper abdomen that produces digestive enzymes (which travel through the pancreatic ducts into the small intestine) and hormones such as insulin and glucagon (which are released into the bloodstream). Pancreatic adenocarcinoma, also called pancreatic ductal adenocarcinoma (PDAC), is the most common type of pancreatic cancer and arises from the cells lining the pancreatic ducts. It is responsible for the great majority of pancreatic cancers and is generally what people mean when they refer to “pancreatic cancer.” Less common types include neuroendocrine tumors, acinar cell carcinomas, intraductal papillary mucinous neoplasms with invasive cancer, and other rarer forms.
Pancreatic adenocarcinoma most often develops in the head of the pancreas (where the pancreatic duct joins the bile duct before emptying into the duodenum), but it can also occur in the body, tail, or uncinate process. Tumors in the head of the pancreas often produce earlier signs because they are more likely to obstruct the common bile duct, causing jaundice. Tumors in the body and tail typically produce more vague symptoms and are often detected at a later stage. The disease is known for its tendency to invade surrounding structures—including major blood vessels and nerves—and to spread to lymph nodes, the liver, the peritoneum, and other organs.
Several factors increase the risk of pancreatic adenocarcinoma, although many patients have no identifiable risk factor. Recognized contributors include older age, smoking (one of the strongest modifiable risk factors), obesity, type 2 diabetes (which can be both a risk factor and an early manifestation), heavy alcohol use, chronic pancreatitis, occupational exposures to certain chemicals, and a personal or family history of pancreatic cancer. Genetic conditions—such as hereditary pancreatitis, BRCA1 and BRCA2 mutations, Lynch syndrome, Peutz-Jeghers syndrome, familial atypical multiple mole melanoma (FAMMM) syndrome with CDKN2A mutations, and others—significantly increase risk and may warrant specific screening in carefully selected patients. New-onset diabetes in older adults, particularly when accompanied by unintentional weight loss, can sometimes be an early sign of pancreatic cancer.
Symptoms develop gradually and depend on tumor location. Painless jaundice—with yellowing of the skin and eyes, dark urine, pale stools, and itching—is a classic presentation of tumors in the head of the pancreas obstructing the bile duct. Other common features include unintentional weight loss, loss of appetite, upper abdominal or mid-back pain (often dull, persistent, and worse at night or after meals), fatigue, nausea, and changes in bowel habits, including fatty or oily stools (steatorrhea). New-onset diabetes or rapid worsening of preexisting diabetes is increasingly recognized as an important warning sign. Less commonly, patients present with blood clots (such as deep vein thrombosis or pulmonary embolism), depression, or other constitutional symptoms before the cancer is identified. Advanced disease may produce ascites, leg swelling, severe abdominal pain, or symptoms related to distant spread.
Diagnosis combines clinical assessment, laboratory tests, and imaging, with tissue confirmation when possible. Blood tests typically include liver function tests (often showing a “cholestatic” pattern in patients with biliary obstruction), fasting glucose and HbA1c, complete blood count, and tumor markers such as CA 19-9 and CEA, which may be elevated but are not specific. Imaging plays a central role. CT with a dedicated “pancreatic protocol” is the primary imaging study and provides detailed information about the location and size of the tumor, vascular involvement, lymph node enlargement, and distant spread, and is widely used for staging and surgical planning. MRI with MR cholangiopancreatography (MRCP) is particularly valuable for evaluating biliary and pancreatic ductal involvement, characterizing complex lesions, and assessing the liver. Endoscopic ultrasound (EUS) provides high-resolution imaging and allows fine-needle biopsy of suspicious lesions—often the preferred way to obtain tissue diagnosis. Endoscopic retrograde cholangiopancreatography (ERCP) is generally used for biliary drainage and sampling. PET/CT is used selectively. Molecular and genetic testing is increasingly important for guiding treatment and may identify actionable targets such as BRCA1/2, PALB2, ATM, microsatellite instability, KRAS G12C, NTRK fusions, and others.
Important to Know
Treatment of pancreatic adenocarcinoma is highly individualized and depends on the location and stage of the tumor, the involvement of major blood vessels and nearby organs, molecular features, and the patient’s overall health. Care is best delivered in centers with pancreatic cancer expertise and multidisciplinary teams that include hepatobiliary or pancreatic surgeons, medical and radiation oncologists, gastroenterologists, interventional radiologists, dietitians, pain specialists, palliative care providers, and others.
Surgical resection offers the best chance for long-term control or cure but is feasible only in a subset of patients. For tumors in the head of the pancreas, pancreaticoduodenectomy (the Whipple procedure) is the standard operation; for tumors in the body or tail, distal pancreatectomy (sometimes with splenectomy) is performed. In selected patients, more extensive resections involving major blood vessels can be considered at experienced centers. Pancreatic cancer is now generally classified as resectable, borderline resectable, locally advanced, or metastatic, and treatment plans are adapted accordingly. In many patients, particularly those with borderline resectable or locally advanced disease, chemotherapy (often combined with radiation in selected cases) is given before surgery (neoadjuvant therapy) to improve the chance of complete removal.
Chemotherapy is a cornerstone of treatment in both the perioperative setting and for advanced disease. Common regimens include modified FOLFIRINOX (a combination of multiple chemotherapy drugs) and gemcitabine combined with nab-paclitaxel, with the choice based on individual factors such as age, performance status, organ function, and tumor features. After surgery, adjuvant chemotherapy is now standard in many situations to reduce the risk of recurrence. For advanced or metastatic disease, chemotherapy can extend survival, control symptoms, and improve quality of life in many patients.
Targeted and immune therapies are increasingly important for patients whose tumors have specific molecular features. Examples include PARP inhibitors for patients with BRCA1/2 or PALB2 mutations after platinum-based chemotherapy, immunotherapy for tumors with microsatellite instability, NTRK or RET inhibitors for rare fusions, KRAS G12C inhibitors in selected patients, and other agents tied to molecular results. Clinical trial participation is particularly important given the limited number of effective standard options and rapid evolution of the field.
Radiation therapy is used in selected patients—often in combination with chemotherapy—for borderline resectable, locally advanced, or recurrent disease, and for palliation of specific symptoms.
Management of complications and symptoms is critical. Endoscopic or percutaneous biliary drainage with stent placement is commonly used to relieve jaundice, reduce itching, prevent cholangitis, and support nutrition and treatment. Pancreatic enzyme replacement therapy is widely used to treat exocrine pancreatic insufficiency, which is very common in patients with pancreatic cancer and significantly affects nutrition and quality of life. Management of pain, including with medications, nerve blocks, or palliative procedures, can substantially improve quality of life. Treatment of diabetes, nutritional support (often in collaboration with dietitians), and prevention and treatment of blood clots—which are common in pancreatic cancer—are important parts of care.
Supportive and palliative care play important roles throughout the course of disease. Early integration of palliative care—even alongside active cancer treatment—is associated with improved quality of life and, in some studies, improved survival. Psychological support, social work involvement, advance care planning, and family-centered care are essential components.
Patients with strong family histories of pancreatic cancer, recognized genetic predisposition syndromes, or other significant risk factors may be candidates for surveillance programs in specialized centers. These programs typically use combinations of MRI and endoscopic ultrasound at defined intervals.
Care is best coordinated by multidisciplinary teams that include the specialists noted above. Imaging and laboratory findings are interpreted alongside the patient’s symptoms, examination, and broader clinical context rather than in isolation.
Red flag symptoms include rapidly progressive jaundice; severe upper abdominal or back pain; high fever with chills (which may suggest cholangitis); persistent vomiting; significant unintentional weight loss; new or rapidly worsening diabetes; sudden severe leg pain or swelling with shortness of breath (which may suggest blood clots); signs of gastrointestinal bleeding; sudden confusion, severe lethargy, or difficulty arousing; or signs of severe infection or shock. These warrant prompt or urgent medical evaluation, as they may indicate cholangitis, biliary obstruction, blood clots, or other serious complications of pancreatic cancer.